PARP1 and acute myeloid leukemia: They also reported features of PARPi-related MDS/AML cases derived from WHO’s pharmacovigilance database (VigiBase): for the 99 cases of MDS and 79 cases of AML collected, the median latency period since first exposure to a PARP inhibitor was 17.8 months, and 45% of cases resulted in death.